Division of Surgical Oncology, Department of Surgery, Loma Linda University, Loma Linda, CA, USA.
Division of Breast Surgery, Department of Surgery, Washington University, St. Louis, MO, USA.
Breast Cancer Res Treat. 2024 Dec;208(3):511-521. doi: 10.1007/s10549-024-07442-3. Epub 2024 Aug 3.
Fragmentation of care (FC, the receipt of care at > 1 institution) has been shown to negatively impact cancer outcomes. Given the multimodal nature of breast cancer treatment, we sought to identify factors associated with FC and its effects on survival of breast cancer patients.
A retrospective analysis was performed of surgically treated, stage I-III breast cancer patients in the 2004-2020 National Cancer Database, excluding neoadjuvant therapy recipients. Patients were stratified into two groups: FC or non-FC care. Treatment delay was defined as definitive surgery > 60 days after diagnosis. Multivariable logistic regression was performed to identify factors predictive of FC, and survival was compared using Kaplan-Meier and multivariable Cox proportional hazards methods.
Of the 531,644 patients identified, 340,297 (64.0%) received FC. After adjustment, FC (OR 1.27, 95% CI 1.25-1.29) was independently associated with treatment delay. Factors predictive of FC included Hispanic ethnicity (OR 1.04, 95% CI: 1.01-1.07), treatment at comprehensive community cancer programs (OR 1.06, 95% CI: 1.03-1.08) and integrated network cancer programs (OR 1.55, 95% CI: 1.51-1.59), AJCC stage II (OR 1.06, 95% CI 1.05-1.07) and stage III tumors (OR 1.06, 95% CI: 1.02-1.10), and HR + /HER2 + tumors (OR 1.05, 95% CI: 1.02-1.07). Treatment delay was independently associated with increased risk of mortality (HR 1.23, 95% CI 1.20-1.26), whereas FC (HR 0.87, 95% CI 0.86-0.88) showed survival benefit.
While treatment delay negatively impacts survival in breast cancer patients, our findings suggest FC could be a marker for multispecialty care that may mitigate some of these effects.
碎片化的医疗护理(FC,即在超过 1 家医疗机构接受护理)已被证明会对癌症治疗结果产生负面影响。鉴于乳腺癌治疗的多模式性质,我们旨在确定与 FC 相关的因素及其对乳腺癌患者生存的影响。
对 2004 年至 2020 年国家癌症数据库中接受手术治疗的 I-III 期乳腺癌患者进行回顾性分析,不包括新辅助治疗的患者。患者分为两组:FC 组或非 FC 组。治疗延迟定义为明确的手术时间距诊断后超过 60 天。采用多变量逻辑回归分析确定 FC 的预测因素,并采用 Kaplan-Meier 和多变量 Cox 比例风险方法比较生存情况。
在确定的 531644 名患者中,340297 名(64.0%)接受了 FC 治疗。调整后,FC(OR 1.27,95%CI 1.25-1.29)与治疗延迟独立相关。FC 的预测因素包括西班牙裔种族(OR 1.04,95%CI:1.01-1.07)、综合社区癌症计划治疗(OR 1.06,95%CI:1.03-1.08)和综合网络癌症计划治疗(OR 1.55,95%CI:1.51-1.59)、AJCC 分期 II 期(OR 1.06,95%CI 1.05-1.07)和 III 期肿瘤(OR 1.06,95%CI:1.02-1.10)以及 HR+/HER2+肿瘤(OR 1.05,95%CI:1.02-1.07)。治疗延迟与死亡风险增加独立相关(HR 1.23,95%CI 1.20-1.26),而 FC(HR 0.87,95%CI 0.86-0.88)显示出生存获益。
虽然治疗延迟会对乳腺癌患者的生存产生负面影响,但我们的研究结果表明,FC 可能是多专科护理的标志,可能减轻其中一些影响。